Suppr超能文献

阻断 IFNAR1 可抑制多发性骨髓瘤驱动的 Treg 扩增和免疫抑制。

Blocking IFNAR1 inhibits multiple myeloma-driven Treg expansion and immunosuppression.

机构信息

Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.

Department of Hematology, Kumamoto University Hospital, Kumamoto, Japan.

出版信息

J Clin Invest. 2018 Jun 1;128(6):2487-2499. doi: 10.1172/JCI88169. Epub 2018 May 14.

Abstract

Despite significant advances in the treatment of multiple myeloma (MM), most patients succumb to disease progression. One of the major immunosuppressive mechanisms that is believed to play a role in myeloma progression is the expansion of regulatory T cells (Tregs). In this study, we demonstrate that myeloma cells drive Treg expansion and activation by secreting type 1 interferon (IFN). Blocking IFN α and β receptor 1 (IFNAR1) on Tregs significantly decreases both myeloma-associated Treg immunosuppressive function and myeloma progression. Using syngeneic transplantable murine myeloma models and bone marrow (BM) aspirates of MM patients, we found that Tregs were expanded and activated in the BM microenvironment at early stages of myeloma development. Selective depletion of Tregs led to a complete remission and prolonged survival in mice injected with myeloma cells. Further analysis of the interaction between myeloma cells and Tregs using gene sequencing and enrichment analysis uncovered a feedback loop, wherein myeloma-cell-secreted type 1 IFN induced proliferation and expansion of Tregs. By using IFNAR1-blocking antibody treatment and IFNAR1-knockout Tregs, we demonstrated a significant decrease in myeloma-associated Treg proliferation, which was associated with longer survival of myeloma-injected mice. Our results thus suggest that blocking type 1 IFN signaling represents a potential strategy to target immunosuppressive Treg function in MM.

摘要

尽管多发性骨髓瘤(MM)的治疗取得了重大进展,但大多数患者仍因疾病进展而死亡。人们认为,一种主要的免疫抑制机制在骨髓瘤进展中起作用,那就是调节性 T 细胞(Treg)的扩增。在这项研究中,我们证明骨髓瘤细胞通过分泌 I 型干扰素(IFN)来驱动 Treg 的扩增和激活。在 Treg 上阻断 IFN α 和 β 受体 1(IFNAR1)可显著降低骨髓瘤相关 Treg 的免疫抑制功能和骨髓瘤的进展。使用同种异体可移植的鼠骨髓瘤模型和 MM 患者的骨髓(BM)抽吸物,我们发现 Treg 在骨髓瘤发展的早期就在 BM 微环境中扩增和激活。选择性耗尽 Treg 可导致接受骨髓瘤细胞注射的小鼠完全缓解和延长生存。使用基因测序和富集分析进一步分析骨髓瘤细胞与 Treg 之间的相互作用,揭示了一个反馈回路,其中骨髓瘤细胞分泌的 I 型 IFN 诱导 Treg 的增殖和扩增。通过使用 IFNAR1 阻断抗体治疗和 IFNAR1 敲除 Treg,我们证明骨髓瘤相关 Treg 的增殖显著减少,这与接受骨髓瘤细胞注射的小鼠的生存时间延长有关。因此,我们的结果表明,阻断 I 型 IFN 信号代表了靶向 MM 中免疫抑制性 Treg 功能的一种潜在策略。

相似文献

7
Evaluating the role of Tregs in the progression of multiple myeloma.评估调节性 T 细胞在多发性骨髓瘤进展中的作用。
Leuk Lymphoma. 2019 Sep;60(9):2134-2142. doi: 10.1080/10428194.2019.1579324. Epub 2019 Feb 18.

引用本文的文献

本文引用的文献

4
IP-10/CXCL10 attracts regulatory T cells: Implication for pancreatic cancer.IP-10/CXCL10吸引调节性T细胞:对胰腺癌的意义。
Oncoimmunology. 2015 Apr 2;4(9):e1027473. doi: 10.1080/2162402X.2015.1027473. eCollection 2015 Sep.
8
The future of immune checkpoint therapy.免疫检查点疗法的未来。
Science. 2015 Apr 3;348(6230):56-61. doi: 10.1126/science.aaa8172.
9
Immune checkpoint blockade in hematologic malignancies.血液恶性肿瘤的免疫检查点阻断。
Blood. 2015 May 28;125(22):3393-400. doi: 10.1182/blood-2015-02-567453. Epub 2015 Apr 1.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验